PHILADELPHIA – Group K Diagnostics has raised $2 million in Series A funding to expand its laboratory infrastructure. The company’s microfluidic point-of-care device, called the MultiDiagnostic, provides test results in 20 minutes, allowing patients to have direct access to their medical results and enabling doctors to adjust medical treatments sooner. “The growth and expansion enabled by this investment brings our team closer to making our mission a reality—providing reliable, affordable test results to patients, and giving providers the opportunity to take immediate therapeutic action based on those results,” said Brianna Wronko, CEO of Group K Diagnostics, in a statement. “We are looking to the future of both our company and the industry, and expect this funding will open many doors for us.” GKD is looking to obtain clearance from the U.S. Food and Drug Administration for the device, and is working on a clinical trial for liver function testing.
You are here: / / Group K Diagnostics raises $2M for lab test device